



ACTIONABLE IDEAS FOR THE ACTIVE INVESTOR

ALPHA INSIGHTS

IDEA GENERATOR LAB

JEFFREY W. HUGE, CMT

CHIEF INVESTMENT OFFICER

JWH INVESTMENT PARTNERS

612.963.4777

JHUGE@JWHINVESTMENT.COM

JUNE 22, 2022

Top Actionable Idea of the Week

Meridian Bioscience, Inc. (VIVO), is a small-cap life science company, that develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. They have recently indicated that their inhibitor-tolerant qPCR mixes are perfect for developing “Monkeypox” assays without further need for optimization. VIVO reports their 3Q22 quarterly results on August 5, at 8:00 AM ET. <https://www.meridianbioscience.com/>

The shares of VIVO posted a new 52-week high yesterday, penetrating a key resistance level to resolve a multi-month base formation of the “Cup & Handle” variety. This base appears to be part of a larger degree bearish-to-bullish reversal pattern. The bullish inflection above \$29, if sustained, projects a measured move to approximately \$41 initially (+36%), then \$49 (+63%) longer-term. $[(\$29 - \$17) + \$29 = \$41]$; $[(\$27 - \$5) + \$27 = \$49]$. An initial stop-loss provision set at \$27.50 would limit the downside to ~ 8% of capital at risk, and establish a very attractive > 4:1 positive risk skew. **Charts 1 & 2**

VIVO is leading the Health Care sector, and the Biotech sub-sector, as well as the S&P 600 and S&P 500 indexes. It has seen a marked acceleration in its momentum relative to the benchmark over the past four weeks. **Chart 3**

From a purely relative strength perspective, the VIVO / SPY ratio appears poised to break out above chart resistance to resolve a structural base formation. Our proprietary Alpha Trend Model has turned positive in March, which adds confidence to the call with respect to the strength of the relative trend. **Chart 4**

TRADE IDEA: Long VIVO

ENTRY PRICE: \$30 Limit

PROFIT TARGET: \$41, then \$49

INITIAL STOP-LOSS: \$27.50

POSITION SIZE: 5% Max

Performance Update. **Charts 5 & 6**

MERIDIAN BIOSCIENCE - WEEKLY


Profit Target = \$41.00; Stop-Loss = \$27.50



Source: StockCharts.com

MERIDIAN BIOSCIENCE - MONTHLY

Profit Target = \$49.00; Stop-Loss = \$24.00




Source: StockCharts.com

RELATIVE STRENGTH ANALYSIS

VIVO is leading the Health Care sector, and the Biotech sub-sector, as well as the S&P 600 and S&P 500 indexes. It has seen a marked acceleration in its momentum relative to the benchmark over the past four weeks.

Weekly Relative Strength Profile



4 weeks ending Jun 21, 2022

chart	visible	tail	symbol	name	sector	industry	price	%chg
#1	<input checked="" type="checkbox"/>	<div style="width: 100%; height: 10px; background-color: green;"></div>	VIVO	Meridian Bioscience Inc.	Health Care	Medical Supplies	29.68	<div style="width: 6.5%; height: 10px; background-color: green;"></div> 6.5
#2	<input checked="" type="checkbox"/>	<div style="width: 100%; height: 10px; background-color: blue;"></div>	XBI	SPDR S&P Biotech ETF			72.65	<div style="width: 2.2%; height: 10px; background-color: green;"></div> 2.2
#3	<input checked="" type="checkbox"/>	<div style="width: 100%; height: 10px; background-color: green;"></div>	XLV	Health Care Select Sector SPDR Fund			125.25	<div style="width: -6.1%; height: 10px; background-color: red;"></div> -6.1
#4	<input checked="" type="checkbox"/>	<div style="width: 100%; height: 10px; background-color: gray;"></div>	\$SPX	S&P 500 Large Cap Index			3789.13	<div style="width: -8.9%; height: 10px; background-color: red;"></div> -8.9
#5	<input checked="" type="checkbox"/>	<div style="width: 100%; height: 10px; background-color: gray;"></div>	\$SPX	S&P 500 Large Cap Index			3789.13	<div style="width: -8.9%; height: 10px; background-color: red;"></div> -8.9
#6	<input checked="" type="checkbox"/>	<div style="width: 100%; height: 10px; background-color: green;"></div>	IJR	iShares Core S&P Small-Cap ETF			91.20	<div style="width: -10.7%; height: 10px; background-color: red;"></div> -10.7

Source: StockCharts.com

ALPHA TREND MODEL

VIVO / SPY Ratio w/ Alpha Trend Model



Source: StockCharts.com

OPEN POSITIONS/ORDERS UPDATE

Open Positions

TradeExchange											Products	Orders	Positions	Jeffrey Huge
Date	Symbol	QTY	Entry Price	Current Price	Total P&L	Return	Profit Target	Stop Type	Stop Loss	Product				
06/15/2022 2:24 pm	SAFM	24	\$208.13	\$208.16	\$0.82	0.02%	\$250	Stop	\$196.00	Idea Generator				

Open Orders

TradeExchange											Products	Orders	Positions	Jeffrey Huge
Date	Sym	QTY	AP	EP	PT	SL	Stop Type	Order Type	Term	Total Cost	Alloc.	Product		
06/08/2022 11:53 am	SCI	69	\$72.10	\$72.10	\$87	\$68.00	Stop Loss	Stop Limit	gtc	\$4,974.90	5%	Idea Generator		
05/11/2022 2:11 pm	GLD	28		\$178	\$235	\$166.00	Stop Loss	Stop Market	gtc	\$4,984	5%	Idea Generator		

Source: TradeExchange.com

PORTFOLIO PERFORMANCE UPDATE

Aggregate performance statistics since inception date (11/15/21).



Source: TradeExchange.com

DISCLAIMER

- ❑ JWH Investment Partners, LLC (“JWH”), any JWH officers or employees, or any third party data provider, shall not be held liable for any loss sustained by anyone who has relied on the information contained in any JWH publication. JWH, the author, is not a registered investment advisor. This document is not intended for public use or distribution.
- ❑ This report expresses the opinions and views of the author as of the date indicated and are based on the author's interpretation of the concepts therein, and may be subject to change without notice. JWH has no duty or obligation to update the information contained herein. Further, JWH makes no representation, and it should not be assumed, that past investment performance is an indication of future results. Moreover, wherever there is the potential for profit there is also the possibility of loss. The information provided in this report is based on technical analysis. Technical analysis is generally based on the study of price movement, volume, sentiment, and trading flows in an attempt to identify and project price trends. Technical analysis does not consider the fundamentals of the underlying corporate issuer. The investments discussed or recommended in this report may not be suitable for all investors. This memorandum is being made available for educational purposes only and should not be used for any other purpose. The information contained herein does not constitute and should not be construed as representation or solicitation for the purchase or sale of any security or related financial instruments in any jurisdiction. Certain information contained herein concerning economic trends, fundamentals, technical analysis, and performance is based on or derived from information provided by independent third-party sources.
- ❑ Readers should conduct their own review and exercise judgment prior to investing. Investments are not guaranteed, involve risk and may result in a loss of principal. Past performance does not guarantee future results. Investments are not suitable for all types of investors. JWH believes that the sources from which such information has been obtained are reliable; however, it cannot guarantee the accuracy of such information and has not independently verified the accuracy or completeness of such information or the assumptions on which such information is based. From time to time JWH, its officers and associates, or their family members may have a position in the securities mentioned in this report. This report, including the information contained herein, has been prepared exclusively for the use of JWH clients, and may not be copied, reproduced, redistributed, republished, or posted in whole or in part, in any form without the prior written consent of JWH.
- ❑ Copyright 2022 © JWH Investment Partners, LLC. All rights reserved.